NCT05980052Recruiting
Goal Setting to Promote Physical Activity Adherence in Midlife Adults
Goal Setting to Promote Physical Activity Adherence in Midlife to Reduce Risk of Alzheimer's Disease and Related-Dementias: A Randomized Mechanistic Proof-Of-Concept Trial
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
Engaging in regular physical activity during midlife is a key lifestyle behavior associated with reduced risk for Alzheimer's disease and related dementias (AD/ADRD). Yet nearly half of midlife adults (48%) do not meet national physical activity guidelines. The purpose of this mechanistic trial is to identify effective goal setting techniques to enhance psychosocial processes of self-regulation for the successful promotion of PA and adherence to national PA guidelines among midlife adults, with the long-term goal of reducing AD/ADRD risk
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 17 Jul 2023
- Start date
- 17 Jul 2023
- Primary completion date
- 31 May 2027
- Lead sponsor
- Arizona State University
- Diseases
- Alzheimer disease
- NCT number
- NCT05980052
What you commit to
- Study type: Interventional
- Planned participants: 144
- From 17 Jul 2023 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Montreal Cognitive Assessment (MoCA) at the study orientation session. A score \< 26 is an exclusion criterion for US born participants. A score of \<23 is an exclusion for participants born outside of the US who completed their high school education in a country where English is not the primary language.
- Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric)
- Currently taking 2 or more ant-depression drugs
Other illness
- History of stroke
Other
- Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided
- Resting blood pressure greater than 200/110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided)
- Pregnant or planning to become pregnant in next 8-months (Phase 1) or 12 months (Phase 2)
- Plans to relocate out of metropolitan Phoenix, Arizona area in the next 8-months (Phase 1) or 12 months (Phase 2)
- Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention
- Score of 16 or higher on the Center for Epidemiological Studies-Depression Scale (CES-D)
- Self-reported current diagnosis of major depression
- Incarcerated individuals (i.e., Prisoners)
Who the study is looking for
- Aged 45 to 65 years
- BMI between 30 kg/m2 to 50 kg/m2
- Participants must weigh a minimum of 110 pounds
- Engaging in 60 minutes or less of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire)
- Self-reported ownership of a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a Fitbit activity monitor)
Age in the registry: 45 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Arizona State University Coordinator of this site? Confirm its status | Phoenix | United States | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.